SAB Biotherapeutics (SABS) Return on Capital Employed (2021 - 2026)
SAB Biotherapeutics' (SABS) quarterly Return on Capital Employed came in at 28.98% in Q1 2026, up 10527.0% YoY from N/an in Q1 2025, and up 0.89% on a QoQ basis from 29.23% in Q4 2025.
SAB Biotherapeutics (SABS) Return on Capital Employed (2021 - 2026) Analysis & Trends
SAB Biotherapeutics (SABS) has 6 years of Return on Capital Employed data on file, last reported at 28.98% in Q1 2026.
- Quarterly Return on Capital Employed rose 10527.0% year-over-year to 28.98% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 28.98% (up 10527.0% YoY) and the FY2025 annual result came in at 50.04%, up 2646.0% from the prior year.
- Return on Capital Employed advanced to 28.98% in Q1 2026, from 29.23% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 28.98% in Q1 2026 to a low of 178.37% in Q2 2025.
- A 5-year average of 82.56% and a median of 78.77% in 2022 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2025 — Return on Capital Employed sank 10086 bps — and 2026, when it surged 10527 bps.
- Tracing SABS's Return on Capital Employed over 5 years: stood at 78.77% in 2022, then slipped by 7 bps to 84.0% in 2023, then decreased by 25 bps to 104.62% in 2024, then jumped by 72 bps to 29.23% in 2025, then increased by 1 bps to 28.98% in 2026.
- The last three Return on Capital Employed figures came in at 28.98% (Q1 2026), 29.23% (Q4 2025), and 44.99% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | SAB Biotherapeutics | 308.92 Mn | 308.92 Mn | - | -31.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -31.01% |
| Mar 31, 2026 | -28.98% |
| Dec 31, 2025 | -29.23% |
| Sep 30, 2025 | -44.99% |
| Jun 30, 2025 | -178.37% |
| Mar 31, 2025 | -134.24% |
| Dec 31, 2024 | -104.62% |
| Sep 30, 2024 | -105.60% |
| Jun 30, 2024 | -77.50% |
| Mar 31, 2024 | -60.65% |
| Dec 31, 2023 | -84.00% |
| Sep 30, 2023 | -119.33% |
| Jun 30, 2023 | -105.35% |
| Mar 31, 2023 | -89.40% |
| Dec 31, 2022 | -78.77% |
| Sep 30, 2022 | -73.09% |
| Jun 30, 2022 | -51.70% |
| Mar 31, 2022 | -37.65% |
| Dec 31, 2021 | -18.45% |